A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee - Full Text View

Sponsor:	Pfizer
Information provided by (Responsible Party):	Pfizer
ClinicalTrials.gov Identifier:	NCT00565812

Purpose

The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. The efficacy of SD-6010 will be evaluated by radiography using joint space narrowing in the medial tibiofemoral compartment of the study knee as the primary endpoint.

Condition	Intervention	Phase
Osteoarthritis	Drug: SD-6010 Drug: Placebo	Phase II Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Long-Term, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Radiographic Study to Investigate the Safety and Efficacy of Orally Administered SD-6010 in Subjects With Symptomatic Osteoarthritis of the Knee

Resource links provided by NLM:

MedlinePlus related topics: Osteoarthritis X-Rays

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

Assessing the progression rate of joint space narrowing in the study knee of subjects diagnosed with knee OA over a 24-month period. [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Assessing the safety and tolerability of multiple doses of SD-6010 administered long-term in subjects diagnosed with knee OA; [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Assessing the clinical benefit of multiple doses of SD-6010 in subjects diagnosed with knee OA [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Enrollment:	5077
Study Start Date:	November 2007
Study Completion Date:	November 2011
Primary Completion Date:	November 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 200 mg High dose active comparator	Drug: SD-6010 200 mg tablets once a day for 2 years
Active Comparator: 50 mg Low dose active comparator	Drug: SD-6010 50 mg tablets once a day for 2 years
Placebo Comparator: Placebo Placebo comparator to be used for control purposes	Drug: Placebo Placebo tablets once a day for 2 years

Eligibility

Ages Eligible for Study:	40 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects aged >= 40 years with a BMI >= 25 and <= 40 kg/m2
In the past, has been diagnosed with knee OA
Radiographic evidence of OA in the study knee

Exclusion Criteria:

A diagnosis of any other rheumatic disease
Current conditions in the study knee that would confound efficacy
Selected, traditional clinical safety and laboratory parameters

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00565812

Show 150 Study Locations

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Pfizer
ClinicalTrials.gov Identifier:	NCT00565812 History of Changes
Other Study ID Numbers:	A6171016
Study First Received:	November 29, 2007
Last Updated:	January 20, 2012
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

knee Osteoarthritis Disease Modifying Osteoarthritis Drug

Additional relevant MeSH terms:

Osteoarthritis
Osteoarthritis, Knee
Arthritis

Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on February 09, 2012